Latest News & Features
Big Pharma
The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges. 1 July 2021
Americas
Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run. 1 July 2021
Generics
Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts. 1 July 2021
Americas
The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope. 29 June 2021
Big Pharma
Roche subsidiary Genentech received $209.5 million in unnecessary payments from Novartis Pharma for a patent licensing deal and is now refusing to return the payment, the Swiss pharma giant has alleged in a redacted complaint. 29 June 2021
Big Pharma
On June 1, 2021, the Chinese government implemented crucial changes to its patent laws, hoping to create better protections for national and international inventors. 29 June 2021
Americas
Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift. 29 June 2021
Big Pharma
Law firm Barnes & Thornburg has announced the opening of a Boston office, its twentieth in the US, with six partners. 24 June 2021
Europe
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith. 24 June 2021
article
Amendments to Chinese patent law went into effect on June 1, 2021. Some of these amendments have important consequences for life sciences patent practice in China. The most striking change is the establishment of a system for resolving patent disputes in the life sciences. 24 June 2021